Treatment of Chronic Rhinosinusitis With Nasal Polyposis With Oral Steroids Followed by Topical Steroids
| Autor: | Pippa Hopkinson, Martyn Barnes, Peter A. Williamson, Peter T. Donnan, Sriram Vaidyanathan, Brian J. Lipworth |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Rhinology Budesonide medicine.medical_specialty Prednisolone medicine.medical_treatment Anti-Inflammatory Agents Administration Oral Drug Administration Schedule Fluticasone propionate Young Adult Nasal Polyps Double-Blind Method Internal Medicine medicine Humans Sinusitis Topical Steroid Therapy Glucocorticoids Aged Rhinitis Fluticasone business.industry Nasal Sprays General Medicine Middle Aged medicine.disease Nasal spray Anesthesia Chronic Disease Female business medicine.drug Topical steroid |
| Zdroj: | Annals of Internal Medicine. 154:293 |
| ISSN: | 0003-4819 |
| DOI: | 10.7326/0003-4819-154-5-201103010-00003 |
| Popis: | BACKGROUND Chronic rhinosinusitis (CRS) with nasal polyposis is common. The long-term efficacy and safety of approaches to medical management are not well-known. OBJECTIVE To evaluate the efficacy and safety of a 2-week regimen of oral steroid therapy followed by 26 weeks of sequential topical steroid maintenance therapy. DESIGN Parallel randomized trial with computer-generated block randomization and central allocation. Patients and investigators were blinded to group assignment. (ClinicalTrials.gov registration number: NCT00788749) SETTING A specialty rhinology clinic in Tayside, Scotland. PATIENTS 60 adults with CRS and moderate-sized or larger nasal polyps who were referred by their primary physicians for specialty care. INTERVENTIONS Patients were randomly assigned in a 1:1 ratio to receive oral prednisolone, 25 mg/d, or placebo for 2 weeks, followed in both groups by fluticasone propionate nasal drops, 400 µg twice daily, for 8 weeks and then fluticasone propionate nasal spray, 200 µg twice daily, for 18 weeks. MEASUREMENTS Polyp grading (primary outcome), hyposmia score, quality of life, symptoms, nasal patency, adrenal function, and bone turnover. RESULTS The mean decrease in polyp grade from baseline to 2 weeks was 2.1 units (SD, 1.1) in the prednisolone group and 0.1 unit (SD, 1.0) in the placebo group (mean difference between groups, -1.8 units [95% CI, -2.4 to -1.2 units]; P < 0.001). The difference between groups was -1.08 units (CI, -1.74 to -0.42 unit; P = 0.001) at 10 weeks and -0.8 unit (CI, -1.8 to 0.2 unit; P = 0.11) at 28 weeks. The mean decrease in hyposmia score from baseline to 2 weeks was 31.12 mm (SD, 30.1) in the prednisolone group and 1.41 mm (SD, 30.6) in the placebo group (mean difference between groups, -28.33 mm [CI, -42.71 to -13.96 mm]; P = 0.002). The difference between groups was -16.06 mm (CI, -30.99 to -1.13 mm; P = 0.03) at 10 weeks and -12.13 mm (CI, -30.55 to 6.29 mm; P = 0.19) at 28 weeks. Prednisolone therapy resulted in transient suppression of adrenal function and increase in bone turnover after 2 weeks, with a return to baseline at 10 and 28 weeks. LIMITATIONS Patients were referred from primary care to a single-center rhinology clinic, which limits the generalizability of results. Serial measurements of surrogates of nasal inflammation (such as nitric oxide or cytokine levels) were not performed. CONCLUSION Initial oral steroid therapy followed by topical steroid therapy seems to be more effective over 6 months than topical steroid therapy alone in decreasing polyp size and improving olfaction in patients referred for specialty care of CRS with at least moderate nasal polyposis. PRIMARY FUNDING SOURCE Chief Scientist Office, Scotland; National Health Service Tayside Small Grants Scheme; and an Anonymous Trust grant from University of Dundee. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|